Septerna, Inc. (SEPN)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
GPCR Oral Small Molecule Drug Discovery	45.95M	1.08M	151.00K
GPCR Oral Small Molecule Drug Discovery Growth	4174.51%	611.92%	-
Total	45.95M	1.08M	151.00K
Total Growth	4174.51%	611.92%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
United States	45.95M	1.08M	151.00K
United States Growth	4174.51%	611.92%	-
Total	45.95M	1.08M	151.00K
Total Growth	4174.51%	611.92%	-

Data Source: S&P Global Market Intelligence Last updated: May 11, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 12, 2026

Data Sources Report a data error